Core Insights - The article emphasizes the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1]. Group 1: Industry Overview - The biotech, pharma, and healthcare industries are experiencing significant movements, necessitating investors to track developments closely [1]. - The Haggerston BioHealth investing group provides insights into catalysts for investment decisions, including buy and sell ratings, product sales forecasts, and integrated financial analyses [1]. Group 2: Analyst Background - Edmund Ingham, a biotech consultant with over five years of experience, has compiled detailed reports on more than 1,000 companies in the sector [1]. - The investing group led by Ingham caters to both novice and experienced investors, offering comprehensive market analyses and forecasts [1].

Group 1 - Intellia Therapeutics, Inc. (NASDAQ:NTLA) is considered one of the most oversold biotech stocks, with a recent downgrade from Buy to Hold by Jones Trading following the announcement of a patient's death related to their treatment [1][2] - The downgrade was influenced by a key opinion leader call held by Dr. Garcia and Jones Trading to discuss the patient who met Hy's Law criteria, which occurred before the patient's death was announced [2] - Baird has lowered its price target for Intellia's shares to $9 while maintaining a Neutral rating, citing the FDA's hold on the NTLA-2001 treatment and the competitive landscape in the ATTR and HAE markets as significant challenges for commercial adoption [3] Group 2 - Intellia Therapeutics is at the forefront of CRISPR-Cas9 gene-editing technology, focusing on developing treatments for both in vivo and ex vivo applications, with its main initiative, NTLA-2001, targeting transthyretin amyloidosis, a currently incurable disease [4]

Core Insights - CRISPR Therapeutics AG (NASDAQ:CRSP) is identified as one of the most oversold biotech stocks, with Oppenheimer reaffirming an Outperform rating and a $95 price target following the company's Q3 financial results [1] - The company reported a lower-than-expected loss of $1.17 per share, compared to the anticipated loss of $1.26 per share, attributed to reduced R&D spending of $59 million versus the expected $88 million [1] Financial Performance - The collaboration expenses for the gene treatment Casgevy amounted to $57 million for the quarter, indicating a slow launch, while partner Vertex noted an increase in momentum for its debut [2] - The advancements in CRISPR's in vivo initiatives were highlighted, particularly the findings from the Phase 1 study of CTX310 presented at the AHA meeting and published in the New England Journal of Medicine [2] Technological Advancements - CRISPR's SyNTase editing technology, showcased in the CTX460 data, is noted to have significant potential, enhancing the company's existing strategies and in vivo initiatives [3] - The company is recognized as a leader in gene-editing technology, utilizing its proprietary gene sequencing platform to develop precise treatments for diseases requiring DNA modification [3]

Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure:I/we ...

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Canadian penny stocks to buy right now. On November 7, Stifel Nicolaus reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL) and set a $7 price target. AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss A stethoscope. Photo by Pixabay The positive stance comes on the heels of the company reporting a wider-than-expected net loss of $57.1 million in its third quarter, compared to a net loss of $51.1 million ...

Medicus Pharma Ltd (NASDAQ:MDCX) is one of the Canadian penny stocks to buy right now. On November 18, Maxim Group analyst Jason McCarthy maintained a Buy rating on Medicus Pharma Ltd (NASDAQ:MDCX) with a $20 price target, citing the company’s promising pipeline and strategic initiatives. Key drivers include the FDA-supported 505(b)(2) pathway for SkinJect, which has shown a 60% complete response rate in Phase 2 trials for non-invasive basal cell carcinoma, well above typical benchmarks, and the acquisitio ...

Group 1: Semtech Corp Financial Results - Semtech reported third-quarter revenue of $267 million, missing analyst estimates of $268.83 million [1] - The company reported third-quarter adjusted earnings of 48 cents per share, beating estimates of 45 cents per share [1] Group 2: Stock Performance - Semtech shares dipped 7.2% to $65.00 in pre-market trading [2] - Other stocks also experienced declines in pre-market trading, including Arcus Biosciences Inc, which fell 6.7% to $21.63, and Nanobiotix SA, which fell 6.2% to $20.64 [4]

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:25 a.m. ET in Coral Gables, Florida. A live webcast of the presentation will be available in the investors section of the company’s website at www.sept ...

LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in two investor events in December. Event: Piper Sandler 37th Annual Healthcare ConferenceType: Fireside chatDate/Time: Wednesday, December 3, 2025, at 10:00 a.m. ET Event: Noble Capital Markets Virtual Pr ...

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in December: Piper Sandler 37th Annual Healthcare Conference, New York, NYTuesday, December 2, 2025, Fireside Chat – 4:30 p.m. ET8th Annual Evercor ...